1. Update on the medical treatment of metastatic renal cell carcinoma;Ravaud;Eur Urol,2008
2. Renal cell carcinoma guideline;Ljungberg;Eur Urol,2007
3. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor andplatelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship;Mendel;Clin Cancer Res,2003
4. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer;Faivre;J Clin Oncol,2006
5. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients;O'Farrell;Clin Cancer Res,2003